drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00398 | DB01220 | 79 | 1,088 | [
"DDInter1702",
"DDInter1593"
] | Sorafenib | Rifaximin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduc... | Moderate | 1 | [
[
[
79,
24,
1088
]
],
[
[
79,
24,
463
],
[
463,
1,
1088
]
],
[
[
79,
6,
8374
],
[
8374,
45,
1088
]
],
[
[
79,
21,
28803
],
[
28803,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifaximin"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifaximin (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifaximin (Compound)
Sorafenib (Compound) causes Anaemia (Side Effect) and Anaemia (Side Ef... |
DB01148 | DB01619 | 1,128 | 830 | [
"DDInter738",
"DDInter1441"
] | Flavoxate | Phenindamine | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1128,
24,
830
]
],
[
[
1128,
24,
537
],
[
537,
40,
830
]
],
[
[
1128,
63,
1219
],
[
1219,
40,
830
]
],
[
[
1128,
63,
13
],
[
13,
... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound)
Fl... |
DB09030 | DB12364 | 840 | 1,421 | [
"DDInter1945",
"DDInter200"
] | Vorapaxar | Betrixaban | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
840,
25,
1421
]
],
[
[
840,
23,
297
],
[
297,
23,
1421
]
],
[
[
840,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
840,
64,
1091
],
[
1091,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Vorapaxar",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} ... | Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Vorapaxar may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor... |
DB00983 | DB01177 | 480 | 77 | [
"DDInter776",
"DDInter904"
] | Formoterol | Idarubicin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
480,
24,
77
]
],
[
[
480,
6,
6017
],
[
6017,
45,
77
]
],
[
[
480,
18,
10375
],
[
10375,
57,
77
]
],
[
[
480,
7,
5998
],
[
5998,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",... | Formoterol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Formoterol (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Idarubicin (Compound)
Formoterol (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Idarubicin (Compound)
Formoterol... |
DB12001 | DB14568 | 564 | 982 | [
"DDInter7",
"DDInter1000"
] | Abemaciclib | Ivosidenib | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
564,
24,
982
]
],
[
[
564,
63,
1101
],
[
1101,
23,
982
]
],
[
[
564,
64,
976
],
[
976,
24,
982
]
],
[
[
564,
24,
241
],
[
241,
2... | [
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Abemaciclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Abemaciclib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may caus... |
DB00467 | DB00552 | 1,467 | 1,238 | [
"DDInter644",
"DDInter1425"
] | Enoxacin | Pentostatin | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Minor | 0 | [
[
[
1467,
23,
1238
]
],
[
[
1467,
1,
1539
],
[
1539,
62,
1238
]
],
[
[
1467,
40,
1176
],
[
1176,
23,
1238
]
],
[
[
1467,
40,
246
],
[
246,... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentostatin"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a minor interact... | Enoxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Enoxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Pentostatin
Enox... |
DB00773 | DB01235 | 896 | 1,191 | [
"DDInter702",
"DDInter1054"
] | Etoposide | Levodopa | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
896,
24,
1191
]
],
[
[
896,
24,
1307
],
[
1307,
40,
1191
]
],
[
[
896,
7,
7972
],
[
7972,
46,
1191
]
],
[
[
896,
18,
1917
],
[
1917,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Etoposide (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Levodopa (Compound)
Etoposide (Compound) downregulates CDC25B (Gene) and CDC25B ... |
DB00544 | DB00562 | 970 | 1,014 | [
"DDInter757",
"DDInter188"
] | Fluorouracil | Benzthiazide | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Moderate | 1 | [
[
[
970,
24,
1014
]
],
[
[
970,
63,
811
],
[
811,
40,
1014
]
],
[
[
970,
24,
674
],
[
674,
1,
1014
]
],
[
[
970,
24,
359
],
[
359,
4... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzthiazide"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Benzthiazide (Compound)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles ... |
DB00549 | DB09280 | 522 | 1,604 | [
"DDInter1955",
"DDInter1101"
] | Zafirlukast | Lumacaftor | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
522,
24,
1604
]
],
[
[
522,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
522,
24,
573
],
[
573,
24,
1604
]
],
[
[
522,
63,
588
],
[
588,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fesot... |
DB01176 | DB09488 | 537 | 103 | [
"DDInter453",
"DDInter23"
] | Cyclizine | Acrivastine | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
537,
24,
103
]
],
[
[
537,
63,
1405
],
[
1405,
24,
103
]
],
[
[
537,
24,
573
],
[
573,
24,
103
]
],
[
[
537,
40,
830
],
[
830,
2... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Fesoterodine... |
DB01059 | DB08899 | 956 | 129 | [
"DDInter1313",
"DDInter649"
] | Norfloxacin | Enzalutamide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
956,
24,
129
]
],
[
[
956,
24,
918
],
[
918,
1,
129
]
],
[
[
956,
6,
8374
],
[
8374,
45,
129
]
],
[
[
956,
21,
28703
],
[
28703,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Norfloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Norfloxacin (Compound) causes Pruritus (Side Effect) and... |
DB01115 | DB05239 | 336 | 866 | [
"DDInter1291",
"DDInter425"
] | Nifedipine | Cobimetinib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
336,
24,
866
]
],
[
[
336,
24,
214
],
[
214,
63,
866
]
],
[
[
336,
63,
1101
],
[
1101,
24,
866
]
],
[
[
336,
24,
1213
],
[
1213,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and B... |
DB00731 | DB01015 | 1,144 | 1,247 | [
"DDInter1269",
"DDInter1724"
] | Nateglinide | Sulfamethoxazole | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Moderate | 1 | [
[
[
1144,
24,
1247
]
],
[
[
1144,
63,
1029
],
[
1029,
1,
1247
]
],
[
[
1144,
24,
698
],
[
698,
1,
1247
]
],
[
[
1144,
6,
1829
],
[
1829,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfadoxine and Sulfadoxine (Compound) resembles Sulfam... |
DB00857 | DB00902 | 1,387 | 104 | [
"DDInter1768",
"DDInter1168"
] | Terbinafine | Methdilazine | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1387,
24,
104
]
],
[
[
1387,
24,
820
],
[
820,
1,
104
]
],
[
[
1387,
63,
508
],
[
508,
1,
104
]
],
[
[
1387,
24,
401
],
[
401,
6... | [
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Methdilazine (Comp... |
DB01177 | DB01218 | 77 | 1,493 | [
"DDInter904",
"DDInter852"
] | Idarubicin | Halofantrine | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
77,
25,
1493
]
],
[
[
77,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
77,
18,
5998
],
[
5998,
46,
1493
]
],
[
[
77,
18,
2183
],
[
2183,
... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Idarubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Halof... | Idarubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Idarubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Idarubicin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Idarub... |
DB00099 | DB01030 | 440 | 869 | [
"DDInter735",
"DDInter1835"
] | Filgrastim | Topotecan | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
440,
24,
869
]
],
[
[
440,
24,
613
],
[
613,
24,
869
]
],
[
[
440,
24,
310
],
[
310,
63,
869
]
],
[
[
440,
63,
599
],
[
599,
24,... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazi... |
DB00619 | DB00708 | 1,419 | 1,454 | [
"DDInter909",
"DDInter1718"
] | Imatinib | Sufentanil | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Moderate | 1 | [
[
[
1419,
24,
1454
]
],
[
[
1419,
25,
704
],
[
704,
40,
1454
]
],
[
[
1419,
6,
8374
],
[
8374,
45,
1454
]
],
[
[
1419,
21,
28658
],
[
2865... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sufentanil"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
... | Imatinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Sufentanil (Compound)
Imatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sufentanil (Compound)
Imatinib (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by... |
DB00636 | DB01124 | 429 | 1,411 | [
"DDInter408",
"DDInter1828"
] | Clofibrate | Tolbutamide | A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
429,
24,
1411
]
],
[
[
429,
24,
959
],
[
959,
40,
1411
]
],
[
[
429,
63,
245
],
[
245,
40,
1411
]
],
[
[
429,
24,
1296
],
[
1296,
... | [
[
[
"Clofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Clofibrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Clofibrate may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Clofibrate may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00400 | DB08903 | 353 | 996 | [
"DDInter843",
"DDInter170"
] | Griseofulvin | Bedaquiline | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
353,
24,
996
]
],
[
[
353,
6,
8374
],
[
8374,
45,
996
]
],
[
[
353,
21,
28762
],
[
28762,
60,
996
]
],
[
[
353,
63,
883
],
[
883,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Griseofulvin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bedaquiline (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and... |
DB00104 | DB01200 | 966 | 469 | [
"DDInter1323",
"DDInter243"
] | Octreotide | Bromocriptine | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
966,
24,
469
]
],
[
[
966,
24,
1131
],
[
1131,
1,
469
]
],
[
[
966,
21,
28787
],
[
28787,
60,
469
]
],
[
[
966,
40,
1154
],
[
1154,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
],
... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide (Compound) resembles Bromocriptine (Compound)
Octreotide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Bromocriptine (Compound)
Octreotide (Compound) resembles ... |
DB00163 | DB01181 | 1,461 | 1,532 | [
"DDInter1943",
"DDInter906"
] | Vitamin E | Ifosfamide | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1461,
24,
1532
]
],
[
[
1461,
24,
0
],
[
0,
24,
1532
]
],
[
[
1461,
23,
259
],
[
259,
63,
1532
]
],
[
[
1461,
24,
37
],
[
37,
63... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dactinomycin"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept and Rilona... |
DB00361 | DB08908 | 134 | 713 | [
"DDInter1939",
"DDInter564"
] | Vinorelbine | Dimethyl fumarate | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
134,
24,
713
]
],
[
[
134,
24,
4
],
[
4,
24,
713
]
],
[
[
134,
24,
725
],
[
725,
63,
713
]
],
[
[
134,
63,
552
],
[
552,
24,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesu... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Vinorelbine may cause a moderate interaction that could exacerbate disease... |
DB08826 | DB08895 | 1,292 | 976 | [
"DDInter489",
"DDInter1825"
] | Deferiprone | Tofacitinib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1292,
25,
976
]
],
[
[
1292,
24,
1193
],
[
1193,
62,
976
]
],
[
[
1292,
25,
214
],
[
214,
63,
976
]
],
[
[
1292,
24,
1017
],
[
1017,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zin... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Deferiprone may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatin... |
DB09156 | DB09420 | 777 | 1,074 | [
"DDInter964",
"DDInter953"
] | Iopromide | Iodide I-123 | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
777,
24,
1074
]
],
[
[
777,
64,
50
],
[
50,
24,
1074
]
],
[
[
777,
63,
33
],
[
33,
24,
1074
]
],
[
[
777,
24,
278
],
[
278,
24,
... | [
[
[
"Iopromide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Iopromide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasa... | Iopromide may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Iopromide may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may ... |
DB01005 | DB01059 | 995 | 956 | [
"DDInter894",
"DDInter1313"
] | Hydroxyurea | Norfloxacin | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
995,
23,
956
]
],
[
[
995,
23,
872
],
[
872,
40,
956
]
],
[
[
995,
62,
1176
],
[
1176,
1,
956
]
],
[
[
995,
23,
1539
],
[
1539,
... | [
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Hydroxyurea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
... | Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Co... |
DB01229 | DB08889 | 973 | 350 | [
"DDInter1377",
"DDInter299"
] | Paclitaxel | Carfilzomib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
973,
24,
350
]
],
[
[
973,
6,
4973
],
[
4973,
45,
350
]
],
[
[
973,
21,
28762
],
[
28762,
60,
350
]
],
[
[
973,
24,
1270
],
[
1270,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Paclitaxel (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Paclitaxel (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified p... |
DB00675 | DB15066 | 888 | 445 | [
"DDInter1744",
"DDInter821"
] | Tamoxifen | Givosiran | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Major | 2 | [
[
[
888,
25,
445
]
],
[
[
888,
25,
1039
],
[
1039,
24,
445
]
],
[
[
888,
63,
1555
],
[
1555,
24,
445
]
],
[
[
888,
24,
850
],
[
850,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
... | Tamoxifen may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin m... |
DB00675 | DB09291 | 888 | 741 | [
"DDInter1744",
"DDInter1615"
] | Tamoxifen | Rolapitant | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
888,
25,
741
]
],
[
[
888,
23,
1135
],
[
1135,
23,
741
]
],
[
[
888,
24,
479
],
[
479,
23,
741
]
],
[
[
888,
24,
159
],
[
159,
6... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rolapitant
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may c... |
DB00208 | DB11703 | 1,018 | 405 | [
"DDInter1804",
"DDInter9"
] | Ticlopidine | Acalabrutinib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1018,
25,
405
]
],
[
[
1018,
23,
1384
],
[
1384,
24,
405
]
],
[
[
1018,
24,
383
],
[
383,
24,
405
]
],
[
[
1018,
25,
1230
],
[
1230,
... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldr... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfa... |
DB00197 | DB00563 | 1,324 | 663 | [
"DDInter1881",
"DDInter1174"
] | Troglitazone | Methotrexate | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
1324,
24,
663
]
],
[
[
1324,
24,
126
],
[
126,
62,
663
]
],
[
[
1324,
24,
1154
],
[
1154,
63,
663
]
],
[
[
1324,
25,
246
],
[
246,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasir... |
DB00738 | DB06402 | 485 | 1,079 | [
"DDInter1420",
"DDInter1756"
] | Pentamidine | Telavancin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
485,
24,
1079
]
],
[
[
485,
21,
28775
],
[
28775,
60,
1079
]
],
[
[
485,
23,
112
],
[
112,
23,
1079
]
],
[
[
485,
24,
657
],
[
657,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Pentamidine",
"{u} (Compound) causes {v} (Side Effect)",
"Phlebitis"
],
[
"Phlebitis",
"{u} (Side Effect) is ca... | Pentamidine (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Telavancin (Compound)
Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tel... |
DB08880 | DB11575 | 1,510 | 1,676 | [
"DDInter1771",
"DDInter841"
] | Teriflunomide | Grazoprevir | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Grazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common i... | Major | 2 | [
[
[
1510,
25,
1676
]
],
[
[
1510,
25,
868
],
[
868,
24,
1676
]
],
[
[
1510,
64,
1419
],
[
1419,
24,
1676
]
],
[
[
1510,
63,
752
],
[
752,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grazoprevir"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
... | Teriflunomide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Grazoprevir
Teriflunomide may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate... |
DB00405 | DB06702 | 128 | 573 | [
"DDInter517",
"DDInter731"
] | Dexbrompheniramine | Fesoterodine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
128,
24,
573
]
],
[
[
128,
24,
211
],
[
211,
1,
573
]
],
[
[
128,
63,
494
],
[
494,
1,
573
]
],
[
[
128,
24,
100
],
[
100,
24,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodi... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resemble... |
DB00683 | DB01181 | 1,382 | 1,532 | [
"DDInter1212",
"DDInter906"
] | Midazolam | Ifosfamide | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1382,
24,
1532
]
],
[
[
1382,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
1382,
21,
28893
],
[
28893,
60,
1532
]
],
[
[
1382,
63,
1648
],
[
1... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Midazolam (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Ifosfamide (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin an... |
DB00586 | DB00881 | 1,512 | 954 | [
"DDInter537",
"DDInter1554"
] | Diclofenac | Quinapril | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
1512,
24,
954
]
],
[
[
1512,
63,
1638
],
[
1638,
1,
954
]
],
[
[
1512,
24,
664
],
[
664,
1,
954
]
],
[
[
1512,
24,
1523
],
[
1523,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril (Compound) resembles Quinapril (Compou... |
DB00673 | DB11703 | 723 | 405 | [
"DDInter112",
"DDInter9"
] | Aprepitant | Acalabrutinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
723,
25,
405
]
],
[
[
723,
63,
1051
],
[
1051,
24,
405
]
],
[
[
723,
62,
1101
],
[
1101,
24,
405
]
],
[
[
723,
24,
951
],
[
951,
... | [
[
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Bexaro... |
DB00539 | DB01110 | 11 | 86 | [
"DDInter1837",
"DDInter1209"
] | Toremifene | Miconazole | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
11,
24,
86
]
],
[
[
11,
7,
8784
],
[
8784,
45,
86
]
],
[
[
11,
6,
4973
],
[
4973,
45,
86
]
],
[
[
11,
18,
2183
],
[
2183,
57,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Toremifene",
"{u} (Compound) upregulates {v} (Gene)",
"CYP51A1"
],
[
"CYP51A1",
"{u} (Gene) is bound by {v} (Com... | Toremifene (Compound) upregulates CYP51A1 (Gene) and CYP51A1 (Gene) is bound by Miconazole (Compound)
Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Miconazole (Compound)
Toremifene (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Miconazole (Compound)
Toremifene (Compou... |
DB08911 | DB11979 | 1,556 | 1,320 | [
"DDInter1842",
"DDInter625"
] | Trametinib | Elagolix | Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor.[A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1556,
24,
1320
]
],
[
[
1556,
63,
129
],
[
129,
24,
1320
]
],
[
[
1556,
24,
913
],
[
913,
24,
1320
]
],
[
[
1556,
24,
971
],
[
971,
... | [
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Trametinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
... | Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Trametinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apa... |
DB01577 | DB06767 | 1,529 | 732 | [
"DDInter1161",
"DDInter80"
] | Metamfetamine | Ammonium chloride | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions. | Moderate | 1 | [
[
[
1529,
24,
732
]
],
[
[
1529,
74,
1445
],
[
1445,
23,
732
]
],
[
[
1529,
63,
22
],
[
22,
23,
732
]
],
[
[
1529,
1,
633
],
[
633,
... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ammonium chloride"
]
],
[
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases... | Metamfetamine (Compound) resembles Pseudoephedrine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Metamfetamine may cause a mo... |
DB00526 | DB01263 | 1,555 | 859 | [
"DDInter1355",
"DDInter1494"
] | Oxaliplatin | Posaconazole | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1555,
24,
859
]
],
[
[
1555,
24,
112
],
[
112,
23,
859
]
],
[
[
1555,
24,
286
],
[
286,
63,
859
]
],
[
[
1555,
63,
482
],
[
482,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Posaconazole
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hyd... |
DB04574 | DB09098 | 177 | 98 | [
"DDInter684",
"DDInter1700"
] | Estrone sulfate (topical) | Somatrem | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
177,
24,
98
]
],
[
[
177,
24,
159
],
[
159,
63,
98
]
],
[
[
177,
74,
1547
],
[
1547,
24,
98
]
],
[
[
177,
63,
870
],
[
870,
24,
... | [
[
[
"Estrone sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Estrone sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
... | Estrone sulfate may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Estrone sulfate may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatre... |
DB09073 | DB12130 | 951 | 1,017 | [
"DDInter1379",
"DDInter1094"
] | Palbociclib | Lorlatinib | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
951,
24,
1017
]
],
[
[
951,
62,
271
],
[
271,
23,
1017
]
],
[
[
951,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
951,
63,
786
],
[
786,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Palbociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Palbociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarote... |
DB00938 | DB01218 | 455 | 1,493 | [
"DDInter1635",
"DDInter852"
] | Salmeterol | Halofantrine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Moderate | 1 | [
[
[
455,
24,
1493
]
],
[
[
455,
6,
3486
],
[
3486,
45,
1493
]
],
[
[
455,
18,
2183
],
[
2183,
57,
1493
]
],
[
[
455,
21,
28810
],
[
28810,... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Salmeterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)... | Salmeterol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Halofantrine (Compound)
Salmeterol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Salmeterol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused... |
DB00341 | DB00780 | 1,242 | 551 | [
"DDInter343",
"DDInter1440"
] | Cetirizine | Phenelzine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
1242,
24,
551
]
],
[
[
1242,
24,
94
],
[
94,
40,
551
]
],
[
[
1242,
21,
28722
],
[
28722,
60,
551
]
],
[
[
1242,
24,
999
],
[
999,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide (Compound) resembles Phenelzine (Compound)
Cetirizine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Phenelzine (Compound)
Cetirizine may cause a moderate interaction that... |
DB00319 | DB09420 | 790 | 1,074 | [
"DDInter1474",
"DDInter953"
] | Piperacillin | Iodide I-123 | Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
790,
24,
1074
]
],
[
[
790,
40,
339
],
[
339,
24,
1074
]
],
[
[
790,
24,
126
],
[
126,
24,
1074
]
],
[
[
790,
1,
1681
],
[
1681,
... | [
[
[
"Piperacillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Piperacillin",
"{u} (Compound) resembles {v} (Compound)",
"Bacampicillin"
],
[
"Bacampicillin",
"{u} may cau... | Piperacillin (Compound) resembles Bacampicillin (Compound) and Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Piperacillin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction th... |
DB05316 | DB08820 | 749 | 1,478 | [
"DDInter1467",
"DDInter997"
] | Pimavanserin | Ivacaftor | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
749,
24,
1478
]
],
[
[
749,
63,
543
],
[
543,
24,
1478
]
],
[
[
749,
25,
985
],
[
985,
63,
1478
]
],
[
[
749,
24,
1040
],
[
1040,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[... | Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Pimavanserin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may c... |
DB00041 | DB00694 | 1,648 | 51 | [
"DDInter38",
"DDInter485"
] | Aldesleukin | Daunorubicin | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1648,
24,
51
]
],
[
[
1648,
23,
739
],
[
739,
62,
51
]
],
[
[
1648,
23,
1467
],
[
1467,
23,
51
]
],
[
[
1648,
24,
1430
],
[
1430,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when taken with Daunorubicin
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxac... |
DB00554 | DB13620 | 1,027 | 948 | [
"DDInter1478",
"DDInter1499"
] | Piroxicam | Potassium gluconate | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Moderate | 1 | [
[
[
1027,
24,
948
]
],
[
[
1027,
24,
848
],
[
848,
24,
948
]
],
[
[
1027,
40,
1171
],
[
1171,
24,
948
]
],
[
[
1027,
24,
848
],
[
848,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Potassium gluconate
Piroxicam (Compound) resembles Meloxicam (Compound) and Meloxicam may cause a moderate interaction that co... |
DB01174 | DB12010 | 697 | 214 | [
"DDInter1442",
"DDInter785"
] | Phenobarbital | Fostamatinib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
697,
25,
214
]
],
[
[
697,
25,
976
],
[
976,
24,
214
]
],
[
[
697,
63,
723
],
[
723,
24,
214
]
],
[
[
697,
24,
973
],
[
973,
24,... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
... | Phenobarbital may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant ... |
DB06168 | DB09123 | 1,531 | 1,525 | [
"DDInter281",
"DDInter546"
] | Canakinumab | Dienogest | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Moderate | 1 | [
[
[
1531,
24,
1525
]
],
[
[
1531,
64,
1064
],
[
1064,
24,
1525
]
],
[
[
1531,
25,
980
],
[
980,
24,
1525
]
],
[
[
1531,
24,
1303
],
[
1303... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dienogest"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribin... | Canakinumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate i... |
DB00741 | DB00812 | 167 | 998 | [
"DDInter885",
"DDInter1451"
] | Hydrocortisone | Phenylbutazone | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Moderate | 1 | [
[
[
167,
24,
998
]
],
[
[
167,
23,
307
],
[
307,
1,
998
]
],
[
[
167,
63,
362
],
[
362,
1,
998
]
],
[
[
167,
24,
97
],
[
97,
40,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],... | Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Phenylbutazone (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenylbutazone (... |
DB00059 | DB01098 | 1,560 | 14 | [
"DDInter1404",
"DDInter1622"
] | Pegaspargase | Rosuvastatin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Moderate | 1 | [
[
[
1560,
24,
14
]
],
[
[
1560,
24,
671
],
[
671,
24,
14
]
],
[
[
1560,
24,
1657
],
[
1657,
23,
14
]
],
[
[
1560,
24,
517
],
[
517,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Desogestrel a... |
DB09133 | DB09333 | 1,527 | 278 | [
"DDInter965",
"DDInter963"
] | Iothalamic acid | Iopodic acid | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
1527,
24,
278
]
],
[
[
1527,
63,
461
],
[
461,
24,
278
]
],
[
[
1527,
24,
116
],
[
116,
24,
278
]
],
[
[
1527,
24,
1074
],
[
1074,
... | [
[
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],... | Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 an... |
DB00346 | DB11827 | 472 | 433 | [
"DDInter44",
"DDInter669"
] | Alfuzosin | Ertugliflozin | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
472,
24,
433
]
],
[
[
472,
63,
521
],
[
521,
24,
433
]
],
[
[
472,
24,
820
],
[
820,
24,
433
]
],
[
[
472,
25,
609
],
[
609,
24,... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimem... |
DB06237 | DB09112 | 438 | 1,455 | [
"DDInter141",
"DDInter1306"
] | Avanafil | Nitrous acid | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
438,
24,
1455
]
],
[
[
438,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
438,
63,
885
],
[
885,
24,
1455
]
],
[
[
438,
24,
433
],
[
433,
... | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
... | Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and ... |
DB00681 | DB01144 | 1,287 | 1,326 | [
"DDInter85",
"DDInter540"
] | Amphotericin B | Diclofenamide | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
1287,
24,
1326
]
],
[
[
1287,
24,
504
],
[
504,
1,
1326
]
],
[
[
1287,
24,
674
],
[
674,
40,
1326
]
],
[
[
1287,
21,
28975
],
[
28975,... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiaz... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazid... |
DB00208 | DB01240 | 1,018 | 885 | [
"DDInter1804",
"DDInter657"
] | Ticlopidine | Epoprostenol | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1018,
24,
885
]
],
[
[
1018,
24,
1061
],
[
1061,
1,
885
]
],
[
[
1018,
6,
17955
],
[
17955,
45,
885
]
],
[
[
1018,
21,
28996
],
[
2899... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Ticlopidine (Compound) binds P2RY12 (Gene) and P2RY12 (Gene) is bound by Epoprostenol (Compound)
Ticlopidine (Compound) causes Musculoskeletal discomfort... |
DB00278 | DB00758 | 291 | 1,347 | [
"DDInter117",
"DDInter413"
] | Argatroban | Clopidogrel | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Major | 2 | [
[
[
291,
25,
1347
]
],
[
[
291,
64,
1018
],
[
1018,
25,
1347
]
],
[
[
291,
6,
7524
],
[
7524,
45,
1347
]
],
[
[
291,
21,
29802
],
[
29802,... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u... | Argatroban may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Argatroban (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clopidogrel (Compound)
Argatroban (Compound) causes Arterial thromb... |
DB11988 | DB14783 | 270 | 287 | [
"DDInter1321",
"DDInter574"
] | Ocrelizumab | Diroximel fumarate | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
270,
24,
287
]
],
[
[
270,
63,
1101
],
[
1101,
24,
287
]
],
[
[
270,
24,
1619
],
[
1619,
24,
287
]
],
[
[
270,
64,
1510
],
[
1510,
... | [
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib a... |
DB01263 | DB09143 | 859 | 313 | [
"DDInter1494",
"DDInter1701"
] | Posaconazole | Sonidegib | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
859,
25,
313
]
],
[
[
859,
63,
1194
],
[
1194,
23,
313
]
],
[
[
859,
24,
101
],
[
101,
23,
313
]
],
[
[
859,
25,
478
],
[
478,
2... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitid... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and ... |
DB00681 | DB04834 | 1,287 | 276 | [
"DDInter85",
"DDInter1571"
] | Amphotericin B | Rapacuronium | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm. | Moderate | 1 | [
[
[
1287,
24,
276
]
],
[
[
1287,
63,
91
],
[
91,
24,
276
]
],
[
[
1287,
24,
1220
],
[
1220,
24,
276
]
],
[
[
1287,
24,
1448
],
[
1448,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rapacuronium"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
]... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Rapacuronium
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Dexamethaso... |
DB00353 | DB01110 | 588 | 86 | [
"DDInter1187",
"DDInter1209"
] | Methylergometrine | Miconazole | A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
588,
24,
86
]
],
[
[
588,
6,
8374
],
[
8374,
45,
86
]
],
[
[
588,
21,
28666
],
[
28666,
60,
86
]
],
[
[
588,
63,
1101
],
[
1101,
... | [
[
[
"Methylergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Methylergometrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v... | Methylergometrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Miconazole (Compound)
Methylergometrine (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Miconazole (Compound)
Methylergometrine may cause a moderate interaction that could exacer... |
DB00780 | DB09082 | 551 | 659 | [
"DDInter1440",
"DDInter1934"
] | Phenelzine | Vilanterol | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
551,
24,
659
]
],
[
[
551,
24,
1296
],
[
1296,
63,
659
]
],
[
[
551,
1,
1161
],
[
1161,
24,
659
]
],
[
[
551,
25,
222
],
[
222,
... | [
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenelzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
... | Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenelzine (Compound) resembles Selegiline (Compound) and Selegiline may cause a moderate interactio... |
DB00065 | DB11989 | 581 | 1,434 | [
"DDInter923",
"DDInter183"
] | Infliximab | Benznidazole | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
581,
24,
1434
]
],
[
[
581,
24,
788
],
[
788,
24,
1434
]
],
[
[
581,
25,
375
],
[
375,
24,
1434
]
],
[
[
581,
24,
148
],
[
148,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Infliximab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certoli... |
DB06016 | DB11827 | 1,508 | 433 | [
"DDInter300",
"DDInter669"
] | Cariprazine | Ertugliflozin | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1508,
24,
433
]
],
[
[
1508,
63,
959
],
[
959,
24,
433
]
],
[
[
1508,
64,
609
],
[
609,
24,
433
]
],
[
[
1508,
24,
98
],
[
98,
2... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Cariprazine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin... |
DB00346 | DB06699 | 472 | 774 | [
"DDInter44",
"DDInter493"
] | Alfuzosin | Degarelix | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
472,
24,
774
]
],
[
[
472,
63,
521
],
[
521,
1,
774
]
],
[
[
472,
21,
29232
],
[
29232,
60,
774
]
],
[
[
472,
23,
112
],
[
112,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Alfuzosin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Alfuzosin may cause a minor interaction that can l... |
DB00598 | DB06723 | 1,523 | 115 | [
"DDInter1013",
"DDInter58"
] | Labetalol | Aluminum hydroxide | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1523,
23,
115
]
],
[
[
1523,
21,
28845
],
[
28845,
60,
115
]
],
[
[
1523,
24,
870
],
[
870,
23,
115
]
],
[
[
1523,
63,
251
],
[
251,
... | [
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused... | Labetalol (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Aluminum hydroxide (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with... |
DB00570 | DB01097 | 147 | 1,377 | [
"DDInter1936",
"DDInter1033"
] | Vinblastine | Leflunomide | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
147,
25,
1377
]
],
[
[
147,
7,
14025
],
[
14025,
57,
1377
]
],
[
[
147,
18,
4930
],
[
4930,
57,
1377
]
],
[
[
147,
21,
28701
],
[
2870... | [
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Vinblastine",
"{u} (Compound) upregulates {v} (Gene)",
"ACOT9"
],
[
"ACOT9",
"{u} (Gene) is downregulated by {v} (Compound)",... | Vinblastine (Compound) upregulates ACOT9 (Gene) and ACOT9 (Gene) is downregulated by Leflunomide (Compound)
Vinblastine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Leflunomide (Compound)
Vinblastine (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomi... |
DB00500 | DB11095 | 24 | 235 | [
"DDInter1831",
"DDInter505"
] | Tolmetin | Desirudin | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
24,
25,
235
]
],
[
[
24,
24,
578
],
[
578,
24,
235
]
],
[
[
24,
24,
738
],
[
738,
63,
235
]
],
[
[
24,
63,
1061
],
[
1061,
24,
... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib ma... |
DB01169 | DB04948 | 57 | 1,084 | [
"DDInter120",
"DDInter1083"
] | Arsenic trioxide | Lofexidine | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Major | 2 | [
[
[
57,
25,
1084
]
],
[
[
57,
62,
112
],
[
112,
23,
1084
]
],
[
[
57,
64,
618
],
[
618,
24,
1084
]
],
[
[
57,
25,
774
],
[
774,
63,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lofexidine"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Arsenic trioxide may lead to a major life threatening interaction when taken with Abarelix and Abarelix ... |
DB06317 | DB06643 | 1,626 | 1,136 | [
"DDInter630",
"DDInter500"
] | Elotuzumab | Denosumab | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1626,
24,
1136
]
],
[
[
1626,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
1626,
24,
1480
],
[
1480,
63,
1136
]
],
[
[
1626,
64,
1377
],
[
13... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomi... |
DB00277 | DB01159 | 1,031 | 419 | [
"DDInter1791",
"DDInter854"
] | Theophylline | Halothane | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Major | 2 | [
[
[
1031,
25,
419
]
],
[
[
1031,
6,
8374
],
[
8374,
45,
419
]
],
[
[
1031,
24,
629
],
[
629,
24,
419
]
],
[
[
1031,
24,
609
],
[
609,
... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halothane"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Halo... | Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Halothane (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Halothane
Theophylline may c... |
DB00159 | DB00374 | 940 | 1,061 | [
"DDInter903",
"DDInter1852"
] | Icosapent | Treprostinil | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
940,
24,
1061
]
],
[
[
940,
24,
885
],
[
885,
40,
1061
]
],
[
[
940,
6,
4789
],
[
4789,
46,
1061
]
],
[
[
940,
18,
14025
],
[
14025,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Icosapent (Compound) binds PPARG (Gene) and PPARG (Gene) is upregulated by Treprostinil (Compound)
Icosapent (Compound) downregulates ACOT9 (Gene) and ACOT... |
DB00631 | DB08903 | 372 | 996 | [
"DDInter405",
"DDInter170"
] | Clofarabine | Bedaquiline | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
372,
24,
996
]
],
[
[
372,
21,
29267
],
[
29267,
60,
996
]
],
[
[
372,
24,
713
],
[
713,
63,
996
]
],
[
[
372,
24,
848
],
[
848,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Alanine aminotransferase increased"
],
[
"Alanine aminotra... | Clofarabine (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Bedaquiline (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate... |
DB00261 | DB00924 | 702 | 1,405 | [
"DDInter93",
"DDInter454"
] | Anagrelide | Cyclobenzaprine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
702,
24,
1405
]
],
[
[
702,
25,
1302
],
[
1302,
1,
1405
]
],
[
[
702,
24,
1236
],
[
1236,
1,
1405
]
],
[
[
702,
25,
401
],
[
401,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Protriptyline"
],
[
"Pr... | Anagrelide may lead to a major life threatening interaction when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Cyclobenzaprine (Com... |
DB01017 | DB09104 | 1,669 | 286 | [
"DDInter1224",
"DDInter1118"
] | Minocycline | Magnesium hydroxide | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1669,
24,
286
]
],
[
[
1669,
24,
1482
],
[
1482,
23,
286
]
],
[
[
1669,
63,
954
],
[
954,
23,
286
]
],
[
[
1669,
23,
1326
],
[
1326,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and ... |
DB00454 | DB01075 | 1,349 | 1,376 | [
"DDInter1150",
"DDInter569"
] | Meperidine | Diphenhydramine | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
1349,
24,
1376
]
],
[
[
1349,
24,
649
],
[
649,
63,
1376
]
],
[
[
1349,
63,
128
],
[
128,
24,
1376
]
],
[
[
1349,
24,
832
],
[
832,
... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenirami... |
DB01166 | DB09472 | 477 | 1,383 | [
"DDInter379",
"DDInter1693"
] | Cilostazol | Sodium sulfate | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
477,
24,
1383
]
],
[
[
477,
25,
609
],
[
609,
24,
1383
]
],
[
[
477,
24,
643
],
[
643,
24,
1383
]
],
[
[
477,
63,
521
],
[
521,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Cl... | Cilostazol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desve... |
DB00518 | DB08873 | 510 | 74 | [
"DDInter35",
"DDInter221"
] | Albendazole | Boceprevir | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Moderate | 1 | [
[
[
510,
24,
74
]
],
[
[
510,
6,
4973
],
[
4973,
45,
74
]
],
[
[
510,
21,
28882
],
[
28882,
60,
74
]
],
[
[
510,
23,
1220
],
[
1220,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Albendazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Albendazole (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Boceprevir (Compound)
Albendazole may cause a minor interaction that can limit clinical effects wh... |
DB06691 | DB08897 | 849 | 1,429 | [
"DDInter1155",
"DDInter22"
] | Mepyramine | Aclidinium | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
849,
24,
1429
]
],
[
[
849,
63,
352
],
[
352,
24,
1429
]
],
[
[
849,
74,
662
],
[
662,
24,
1429
]
],
[
[
849,
24,
573
],
[
573,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Mepyramine (Compound) resembles Carbinoxamine (Compound) and Mepyramine may cause a moderate interaction that could ... |
DB08899 | DB11952 | 129 | 800 | [
"DDInter649",
"DDInter612"
] | Enzalutamide | Duvelisib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Major | 2 | [
[
[
129,
25,
800
]
],
[
[
129,
25,
466
],
[
466,
62,
800
]
],
[
[
129,
63,
310
],
[
310,
24,
800
]
],
[
[
129,
25,
1476
],
[
1476,
6... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
... | Enzalutamide may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may... |
DB00222 | DB09481 | 245 | 460 | [
"DDInter825",
"DDInter1113"
] | Glimepiride | Magnesium carbonate | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
245,
24,
460
]
],
[
[
245,
24,
664
],
[
664,
23,
460
]
],
[
[
245,
25,
872
],
[
872,
24,
460
]
],
[
[
245,
24,
624
],
[
624,
24,... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perindopril"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Perindopril and Perindopril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Glimepiride may lead to a major life threatening interaction when taken with Gemifloxacin and Gemiflox... |
DB00295 | DB01170 | 475 | 1,150 | [
"DDInter1244",
"DDInter846"
] | Morphine | Guanethidine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
475,
24,
1150
]
],
[
[
475,
6,
8374
],
[
8374,
45,
1150
]
],
[
[
475,
24,
1376
],
[
1376,
24,
1150
]
],
[
[
475,
23,
22
],
[
22,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanethidine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Morphine... |
DB00685 | DB09045 | 1,299 | 52 | [
"DDInter1887",
"DDInter607"
] | Trovafloxacin | Dulaglutide | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1299,
24,
52
]
],
[
[
1299,
24,
170
],
[
170,
23,
52
]
],
[
[
1299,
1,
1467
],
[
1467,
24,
52
]
],
[
[
1299,
25,
870
],
[
870,
2... | [
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Trovafloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that co... |
DB00352 | DB09498 | 482 | 810 | [
"DDInter1814",
"DDInter1715"
] | Tioguanine | Strontium chloride Sr-89 | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
482,
24,
810
]
],
[
[
482,
63,
552
],
[
552,
24,
810
]
],
[
[
482,
24,
1555
],
[
1555,
24,
810
]
],
[
[
482,
24,
1480
],
[
1480,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Oxalipl... |
DB11652 | DB14723 | 1,155 | 159 | [
"DDInter1891",
"DDInter1026"
] | Tucatinib | Larotrectinib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
1155,
25,
159
]
],
[
[
1155,
62,
222
],
[
222,
23,
159
]
],
[
[
1155,
24,
466
],
[
466,
23,
159
]
],
[
[
1155,
64,
1135
],
[
1135,
... | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Tucatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramin... | Tucatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darol... |
DB01211 | DB06212 | 609 | 165 | [
"DDInter393",
"DDInter1833"
] | Clarithromycin | Tolvaptan | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Major | 2 | [
[
[
609,
25,
165
]
],
[
[
609,
64,
1080
],
[
1080,
1,
165
]
],
[
[
609,
6,
8374
],
[
8374,
45,
165
]
],
[
[
609,
21,
28981
],
[
28981,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolvaptan"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
... | Clarithromycin may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tolvaptan (Compound)
Clarithromycin (Compound) causes Renal impairment (Side Effect) and Renal i... |
DB00446 | DB06228 | 597 | 792 | [
"DDInter351",
"DDInter1609"
] | Chloramphenicol | Rivaroxaban | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Moderate | 1 | [
[
[
597,
24,
792
]
],
[
[
597,
24,
453
],
[
453,
40,
792
]
],
[
[
597,
6,
7524
],
[
7524,
45,
792
]
],
[
[
597,
21,
28703
],
[
28703,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
]... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid (Compound) resembles Rivaroxaban (Compound)
Chloramphenicol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Rivaroxaban (Compound)
Chloramphenicol (Compound) causes Pruritus (Side Effect)... |
DB06403 | DB12010 | 1,204 | 214 | [
"DDInter62",
"DDInter785"
] | Ambrisentan | Fostamatinib | Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the Un... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1204,
24,
214
]
],
[
[
1204,
63,
322
],
[
322,
24,
214
]
],
[
[
1204,
62,
600
],
[
600,
24,
214
]
],
[
[
1204,
24,
1478
],
[
1478,
... | [
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Ambrisentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Ambrisentan may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Ambrisentan may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Flu... |
DB00443 | DB06819 | 251 | 754 | [
"DDInter195",
"DDInter1452"
] | Betamethasone | Phenylbutyric acid | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone. It is used to treat genetic metabolic syndromes, neuropathies, and ur... | Moderate | 1 | [
[
[
251,
24,
754
]
],
[
[
251,
1,
891
],
[
891,
24,
754
]
],
[
[
251,
40,
167
],
[
167,
24,
754
]
],
[
[
251,
24,
1236
],
[
1236,
24... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutyric acid"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} m... | Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases w... |
DB06779 | DB09068 | 365 | 1,427 | [
"DDInter470",
"DDInter1948"
] | Dalteparin | Vortioxetine | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
365,
24,
1427
]
],
[
[
365,
64,
25
],
[
25,
24,
1427
]
],
[
[
365,
25,
802
],
[
802,
24,
1427
]
],
[
[
365,
25,
405
],
[
405,
63... | [
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistr... | Dalteparin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Dalteparin may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may cause a moderat... |
DB00213 | DB00880 | 837 | 359 | [
"DDInter1388",
"DDInter360"
] | Pantoprazole | Chlorothiazide | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
837,
24,
359
]
],
[
[
837,
24,
1577
],
[
1577,
1,
359
]
],
[
[
837,
21,
28973
],
[
28973,
60,
359
]
],
[
[
837,
24,
126
],
[
126,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Pantoprazole (Compound) causes Nephritis interstitial (Side Effect) and Nephritis interstitial (Side Effect) is caused by Chlorothiazide (... |
DB00738 | DB00843 | 485 | 479 | [
"DDInter1420",
"DDInter583"
] | Pentamidine | Donepezil | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
485,
24,
479
]
],
[
[
485,
24,
843
],
[
843,
1,
479
]
],
[
[
485,
6,
12523
],
[
12523,
45,
479
]
],
[
[
485,
7,
4622
],
[
4622,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Pentamidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound)
Pentamidine (Compound) upregulates PRKCD (Gene) and PRKCD (G... |
DB00843 | DB11979 | 479 | 1,320 | [
"DDInter583",
"DDInter625"
] | Donepezil | Elagolix | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
479,
24,
1320
]
],
[
[
479,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
479,
63,
79
],
[
79,
24,
1320
]
],
[
[
479,
24,
877
],
[
877,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafen... |
DB00637 | DB01259 | 1,557 | 392 | [
"DDInter128",
"DDInter1024"
] | Astemizole | Lapatinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1557,
24,
392
]
],
[
[
1557,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1557,
18,
10375
],
[
10375,
57,
392
]
],
[
[
1557,
24,
479
],
[
479,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Astemizole (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Lapatinib (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may c... |
DB00563 | DB01053 | 663 | 514 | [
"DDInter1174",
"DDInter189"
] | Methotrexate | Benzylpenicillin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible o... | Major | 2 | [
[
[
663,
25,
514
]
],
[
[
663,
25,
1390
],
[
1390,
1,
514
]
],
[
[
663,
25,
1681
],
[
1681,
40,
514
]
],
[
[
663,
64,
790
],
[
790,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzylpenicillin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticarcillin"
],
[
"Ticarcillin",
... | Methotrexate may lead to a major life threatening interaction when taken with Ticarcillin and Ticarcillin (Compound) resembles Benzylpenicillin (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Mezlocillin and Mezlocillin (Compound) resembles Benzylpenicillin (Compound)
Methotrexa... |
DB00334 | DB00835 | 867 | 100 | [
"DDInter1326",
"DDInter245"
] | Olanzapine | Brompheniramine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
867,
24,
100
]
],
[
[
867,
24,
832
],
[
832,
24,
100
]
],
[
[
867,
24,
649
],
[
649,
63,
100
]
],
[
[
867,
6,
8374
],
[
8374,
45... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Clofedan... |
DB00712 | DB01324 | 1,274 | 178 | [
"DDInter763",
"DDInter1490"
] | Flurbiprofen | Polythiazide | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1274,
24,
178
]
],
[
[
1274,
24,
674
],
[
674,
40,
178
]
],
[
[
1274,
63,
1014
],
[
1014,
40,
178
]
],
[
[
1274,
21,
28835
],
[
28835,... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resemb... |
DB00562 | DB11827 | 1,014 | 433 | [
"DDInter188",
"DDInter669"
] | Benzthiazide | Ertugliflozin | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1014,
24,
433
]
],
[
[
1014,
1,
811
],
[
811,
24,
433
]
],
[
[
1014,
24,
959
],
[
959,
24,
433
]
],
[
[
1014,
63,
251
],
[
251,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a ... | Benzthiazide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that ... |
DB00307 | DB00333 | 1,101 | 576 | [
"DDInter202",
"DDInter1166"
] | Bexarotene | Methadone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
1101,
24,
576
]
],
[
[
1101,
24,
194
],
[
194,
40,
576
]
],
[
[
1101,
23,
998
],
[
998,
40,
576
]
],
[
[
1101,
63,
494
],
[
494,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Methadone (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Methadone (Comp... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.